Evaluation of the Level of Serum Interleukins (IL-2, IL-4, IL-15, and IL-17) and Its Relationship with Disease Severity in Patients with Alopecia Areata

September 2021 in “ Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia ”

Özge Aşkın, Sera Nur Yücesoy, Erkam Coşkun, Burhan Engın, Server Serdaroğlu

alopecia areata interleukin IL-2 IL-4 IL-15 IL-17 tofacitinib AA JAK inhibitor

TLDR Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

The study evaluated serum interleukin levels (IL-2, IL-4, IL-15, and IL-17) in 61 alopecia areata (AA) patients and 30 healthy controls, finding significantly higher levels of IL-2, IL-4, and IL-15 in AA patients. Despite these elevated levels, no significant correlation was found between interleukin levels and disease duration or severity. Among 22 patients treated with tofacitinib, interleukin levels and disease severity significantly decreased after 6 months, but changes in interleukin levels did not correlate with changes in disease severity. This suggests interleukins play a role in AA pathogenesis, though their levels do not directly reflect disease severity or duration.

View this study on sciencedirect.com →

Discuss this study in the Community →

Cited in this study

12 / 12 results

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , October 2019 in “Journal of the European Academy of Dermatology and Venereology”

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

research Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata

11 citations , June 2019 in “Journal of dermatology”

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

research Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients

17 citations , February 2019 in “Dermatologic Therapy”

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature

17 citations , January 2019 in “Journal of cutaneous medicine and surgery”

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

research Alopecia Areata: A Review of Disease Pathogenesis

191 citations , September 2018 in “British journal of dermatology/British journal of dermatology, Supplement”

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management

99 citations , July 2017 in “Clinical Reviews in Allergy & Immunology”

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

research Treatment of Alopecia Areata With Tofacitinib

78 citations , June 2017 in “JAMA Dermatology”

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata

30 citations , May 2016 in “Expert Opinion on Biological Therapy”

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

research Current Treatments for Alopecia Areata

21 citations , November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

16 citations , May 2011 in “Recent Patents on Inflammation & Allergy Drug Discovery”

Alopecia Areata is an autoimmune disease causing hair loss in patches, often starting before age 20, and while some cases recover on their own, treatments include topical corticosteroids, minoxidil, and promising new methods like IL-31 antibodies and 308-nm Excimer laser therapy.

5 / 5 results

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , March 2019 in “Journal of autoimmunity”

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

research Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata

6 citations , March 2019 in “JAAD case reports”

A new mix of anthralin and calcipotriene might help treat severe hair loss.

research Linear Alopecia Areata

4 citations , November 2018 in “JAAD case reports”

Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Treating Resistant Cases of Alopecia Universalis

May 2018 in “Journal of cosmetology & trichology”

Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.